[144] Ginkgo Bioworks Holdings, Inc. SEC Filing

Rhea-AI Filing Summary

Ginkgo Bioworks Holdings, Inc. (DNA) Form 144 notifies the proposed sale of 10,000 Class A shares through Fidelity Brokerage Services with an aggregate market value of $110,599.54. The filing reports the shares were acquired on 03/11/2022 via restricted stock vesting as compensation. The approximate sale date is listed as 09/09/2025 on the NYSE, and the issuer has 47,089,598 shares outstanding. The filer disclosed a prior sale of 10,000 shares on 09/08/2025 that generated gross proceeds of $109,209.34. The notice includes the standard attestation that no undisclosed material adverse information is known.

Positive

• Timely and complete disclosure of acquisition date, nature (restricted stock vesting), broker, and sale details via Form 144
• Low proportional size of the proposed sale (approximately 0.021% of outstanding shares), limiting immediate market impact

Negative

• Insider selling of vested compensation (10,000 shares plus a prior 10,000-share sale the day before) could be viewed negatively by some investors
• No contextual information on purpose of sale or whether a Rule 10b5-1 plan governs the transactions

Insights

Securities/Equity Analyst

TL;DR: Insider sale of 10,000 Class A shares is modest relative to total outstanding shares; transparency maintained via Form 144.

The sale represents roughly 0.021% of Class A shares outstanding (10,000 of 47,089,598), which is immaterial to the companys capital structure. The shares were received as restricted stock vesting in 2022 and classified as compensation, indicating these are non-open-market grants being monetized. The previous days sale of an identical block suggests a staged liquidation, but the absolute size is small. This filing provides useful disclosure but contains no operational or financial metrics to reassess company performance.

Compliance / Governance Analyst

TL;DR: Filing satisfies Rule 144 disclosure requirements; no red flags in form content.

The Form 144 properly identifies acquisition date, nature (restricted stock vesting), broker details, and attestation about material non-public information. The inclusion of a sale on 09/08/2025 and a proposed sale on 09/09/2025 is consistent with required reporting for aggregated sales. There is no indication of trading-plan adoption or other special instructions disclosed on the form. From a governance standpoint, the document meets procedural expectations but does not provide additional context on intent or liquidity planning.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	10000	110599.54	47089598	09/09/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A	03/11/2022	Restricted Stock Vesting	Issuer			10000	03/11/2022	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Christian Henry 27 Drydock Avenue 8th Floor Boston MA 02210	Class A	09/08/2025	10000	109209.34

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filed for Ginkgo Bioworks (DNA) report?

The form reports a proposed sale of 10,000 Class A shares through Fidelity with an aggregate market value of $110,599.54, approximate sale date 09/09/2025, and that the shares were acquired via restricted stock vesting on 03/11/2022 as compensation.

How many shares of Ginkgo Bioworks are outstanding according to the filing?

The filing states there are 47,089,598 shares outstanding.

Did the filer sell any Ginkgo Bioworks shares recently?

Yes. The filing discloses a prior sale on 09/08/2025 of 10,000 Class A shares for gross proceeds of $109,209.34.

How were the shares being sold originally acquired?

The shares were acquired on 03/11/2022 through restricted stock vesting from the issuer and were paid as compensation.

Which broker is handling the proposed sale?

The broker listed is Fidelity Brokerage Services LLC, address shown in the filing.